

Table 1. Description of levels and attributes.

Levels	Attribute 1: IGF-I level control
1	IGF-I levels control in 9 out of 10 patients
2	IGF-I levels control in 6 out of 10 patients
3	IGF-I level control in 3 out of 10 patients
Levels	Attribute 2: Tumour control
1	Reduces tumour size
2	Does not reduce tumour size
Levels	Attribute 3: Administration methods
1	Daily self-administered injection at home
2	Monthly self-administered or nurse-administered injection in primary care/hospital
3	Monthly nurse-administered injection in primary care/hospital
Levels	Attribute 4: Pain associated with method of administration
1	Minimal injection pain and no redness/ bruising/ skin hardening
2	Minimal injection pain but may cause redness/ bruising/ skin hardening
3	Injection may be painful and cause redness/ bruising/ skin hardening
Levels	Attribute 5: Adverse events: diarrhoea
1	Diarrhoea in 1 out of 10 patients
2	Diarrhoea in 3 out of 10 patients
3	Diarrhoea in 4 out of 10 patients
Levels	Attribute 6: Blood sugar control
1	Improved blood sugar (or diabetes), or blood sugar medication down-dosed
2	Blood sugar (or diabetes) or blood sugar medication unaffected
3	Blood sugar higher (or diabetes onset), or blood sugar medication may be required/up-dosed
Levels	Attribute 7: Storage conditions
1	Storage at room temperature
2	Cold storage (fridge)
Levels	Attribute 8: Quality of life
1	Improves quality of life
2	Does not improve quality of life

IGF-I: insulin-like growth factor I